

EXECUTIVE SUMMARY – PATIENT SUPPORT PROGRAMME
COLLABORATIVE PROJECT
Angelini Pharma UK-I
and
Epilepsy Action UK

PROJECT TITLE: Patient Support Programme (PSP) to aid patients during treatment with Angelini product in epilepsy.

WHO ARE EPILEPSY ACTION?

- Epilepsy Action are an award-winning charity who aim to create a 'world without limits' for people with epilepsy. They strive towards this goal through several ways, including providing education about epilepsy, working towards reducing the stigma of epilepsy, providing lifestyle advice which can help manage epilepsy and more.
- Epilepsy Action also have a dedicated helpline for patients to call for support with their condition. The specially trained helpline advisors provide proactive and reactive calls to patients to help them understand their condition and support them when needed.

WHO ARE ANGELINI PHARMA?

- Angelini Pharma is an international pharmaceutical company headquartered in Italy which specialises in brain health.
- Angelini Pharma currently have one drug in the UK which is licensed for specific epilepsy types.

SCOPE AND EXPECTED OUTCOMES

- Patients who are prescribed the Angelini company product within the product license fall within scope of this Patient Support Programme. Enrolled patients will benefit from set proactive calls and unlimited reactive calls from the dedicated Epilepsy Action helpline advisors where they can seek support and guidance regarding their condition and medication.
- The intended outcome of the PSP is to improve the patient experience whilst being treated with Angelini Pharma's product. This includes, but is not limited to, improving knowledge of the disease, aid patient understanding of the drug, what to expect whilst using the drug, educating patients about lifestyle improvements and more.

GOVERNANCE

- Epilepsy Action will be responsible for the handling of personal data of all patients enrolled within the programme. All Epilepsy Action call handlers will abide by their SOPs and relevant documents to ensure they are compliant with the data protection act and other data handling laws.
- Angelini Pharma will receive anonymised reports from Epilepsy Action regarding patients enrolled into the PSP. Any escalations, such as Medical Information enquiries, will remain anonymised and the answer will be passed onto Epilepsy Action to return to the enquirer.

TIMELINE

- Programme Initiation – December 2024
- First Patient In – April 2025
- Programme Termination/ Renewal – July 2026